marijuana stocks

Form 8-K for VAPOR CORP.


28-Jan-2015

Termination of a Material Definitive Agreement, Change in Directors or Principal Offi

Item 1.02 Termination of a Material Definitive AgreementOn January 24, 2015, Vapor Corp. (the “Registrant”) and Knight Global Services, LLC (“Knight Global”) mutually agreed to terminate that certain consulting agreement entered into between the parties on February 3, 2014. Knight Global is an affiliate of Ryan Kavanaugh, a director of the Registrant.

The Registrant and Knight Global mutually agreed to terminate the Consulting Agreement based on the determination that it was in the best interests of both parties to do so. As a result of such termination, the Registrant will issue 50,000 shares of its common stock to Knight Global pursuant to the early termination provisions of the Consulting Agreement.

 

Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.(b)

On January 24, 2015, the Registrant received notice from Ryan Kavanaugh, a director of the Registrant, that he has resigned from the Registrant’s board of directors, effective immediately.

 

 


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

MustGrow Biologics Corp. (MGROF) and Bayer sign Exclusive Agreement

MustGrow and Bayer sign Exclusive Agreement to Develop Sustainable Organic Biologicals in…

Curaleaf Holdings, Inc. (CURLF) First Quarter 2022 Results

Curaleaf Reports First Quarter 2022 Results Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX:…

MariMed Inc. (MRMD) Receives Maryland State Approval for Transfer of Ownership of Kind Therapeutics USA

MariMed Receives Maryland State Approval for Transfer of Ownership of Kind Therapeutics…

GT Biopharma Inc. (GTBP) Announces Completion of First Four Patients in FDA Phase 2 Trial of Cancer Drug OXS-1550

GT Biopharma Announces Completion of First Four Patients in FDA Phase 2…